alzheimer

Pittsburgh Compound B, an imaging agent that could facilitate the early diagnosis of Alzheimer's disease, has been used to identify amyloid deposition in the brains of clinically older adults.

The findings could not only shed more light on how the illness progresses, but also open the door to the possibility of prevention strategies.

People with Alzheimer's disease who also have diabetes or high blood pressure may die sooner than people without such disorders, according to a new study.

The first long-term study of the real-world use of Alzheimer's drugs finds that treatment can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities.

New UCLA research suggests that the treatment of early symptoms of memory loss may protect the brain and help people with mild age-related memory impairment.

The finding also shows how PET offers researchers a tool for tracking the effectiveness of drugs prescribed to treat age-related cognitive decline.

Alzheimer's patients showed rapid improvement in language within minutes of a novel immune-based treatment. A new article provides preliminary evidence that the disrupted neural communication seen in Alzheimer's disease may be reversible.

Researchers have confirmed that in the earliest stages of Alzheimer's, levels of specific proteins in the blood and spinal fluid can be used to track the progression of AD, long before symptoms appear.

The hope is that, one day, screening for such biomarkers could take their place beside such routine tests as colonoscopies and mammograms as another common tool of preventive medicine.

Neuroscientists have succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.

The location of protein-destroying "machines" in nerve cells in the brain may play an important role in how memories are formed -- a finding with potential implications for treating Alzheimer's and other brain diseases.

In studies of human brain cells, the widely-used anesthetic desflurane does not contribute to increased production of amyloid-beta protein; however, when combined with low oxygen conditions, it can produce more of this Alzheimer's associated protein.

Heavy drinkers and heavy smokers develop Alzheimer's disease years earlier than people with Alzheimer's who do not drink or smoke heavily, according to new research.